Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of ...
Morgans analyst Scott Power said investors have dealt with Avita Medical (ASX:AVH) "fairly harshly" after it downgraded its ...
Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...
Rule could make more medications available over the counter through a process called Additional Condition of Non-prescription Use (ACNU).
Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.
On January 6, the FDA announced the availability of draft guidance on accelerated approval for drugs and biological products, and consideration ...
Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.
The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
ViGeneron GmbH, a clinical-stage gene therapy company based in Munich, Germany, shared details of two new milestones in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback